Robert M Matera1, Valerie Relias1, Muhammad Wasif Saif1,2. 1. Tufts Medical Center, Tufts University School of Medicine, Boston, MA, USA. 2. Department of Medical Oncology, Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra and Feinstein Institute for Medical Research, USA.
Abstract
BACKGROUND: Pegfilgrastim is typically administered 24 hours after chemotherapy per package insert; however some patients are unable or unwilling to return for this additional visit due to work or transportation especially with regimens consisting of infusional 5-FU. Same-day dosing eliminates need for this additional visit. Results from prior studies in other tumor types are inconclusive as few support same-day dosing whereas others show inferiority. Purpose of our study was to determine safety and efficacy of administering pegfilgrastim on same day as chemotherapy in patients with gastrointestinal (GI) malignancies. METHOD: A single-institution retrospective review was conducted of 69 patients with GI malignancies who received chemotherapy and same-day pegfilgrastim (6 mg) within 1 hour of completion of chemotherapy from Jan 2014 through Jan 2017. As per institutional guidelines, patients were counseled on risks of same-day pegfilgrastim prior to its administration. These patients were compared with a set of 70 patients who received pegfilgrastim 24-hours after completing the chemotherapy for GI cancers. RESULT: A total of 536 chemotherapy cycles in 69 patients were analyzed. Median absolute neutrophil count nadir for all cycles was 4538/uL (Range: 1160 - 25168). Grade 1 and 2 neutropenia developed in 6 of 536 (1%) cycles. Bone pain reported in 3 patients (4%). There were no episodes of grade 3 or 4 neutropenia or febrile neutropenia. None had dose reductions, chemotherapy delays, hospitalizations, or antibiotic use due to neutropenia. CONCLUSION: We believe our study is the first in GI malignancies to report that same-day pegfilgrastim administration may be as effective and safe as next-day administration, benefiting patients and might reduce costs.
BACKGROUND: Pegfilgrastim is typically administered 24 hours after chemotherapy per package insert; however some patients are unable or unwilling to return for this additional visit due to work or transportation especially with regimens consisting of infusional 5-FU. Same-day dosing eliminates need for this additional visit. Results from prior studies in other tumor types are inconclusive as few support same-day dosing whereas others show inferiority. Purpose of our study was to determine safety and efficacy of administering pegfilgrastim on same day as chemotherapy in patients with gastrointestinal (GI) malignancies. METHOD: A single-institution retrospective review was conducted of 69 patients with GI malignancies who received chemotherapy and same-day pegfilgrastim (6 mg) within 1 hour of completion of chemotherapy from Jan 2014 through Jan 2017. As per institutional guidelines, patients were counseled on risks of same-day pegfilgrastim prior to its administration. These patients were compared with a set of 70 patients who received pegfilgrastim 24-hours after completing the chemotherapy for GI cancers. RESULT: A total of 536 chemotherapy cycles in 69 patients were analyzed. Median absolute neutrophil count nadir for all cycles was 4538/uL (Range: 1160 - 25168). Grade 1 and 2 neutropenia developed in 6 of 536 (1%) cycles. Bone pain reported in 3 patients (4%). There were no episodes of grade 3 or 4 neutropenia or febrile neutropenia. None had dose reductions, chemotherapy delays, hospitalizations, or antibiotic use due to neutropenia. CONCLUSION: We believe our study is the first in GI malignancies to report that same-day pegfilgrastim administration may be as effective and safe as next-day administration, benefiting patients and might reduce costs.
Entities:
Keywords:
Chemotherapy; Fever; Leukopenia; Neutropenia; Pegfilgrastim; Side effects
Authors: N J Meropol; L L Miller; E L Korn; L E Braitman; M L MacDermott; L M Schuchter Journal: J Natl Cancer Inst Date: 1992-08-05 Impact factor: 13.506
Authors: Thomas J Smith; Kari Bohlke; Gary H Lyman; Kenneth R Carson; Jeffrey Crawford; Scott J Cross; John M Goldberg; James L Khatcheressian; Natasha B Leighl; Cheryl L Perkins; George Somlo; James L Wade; Antoinette J Wozniak; James O Armitage Journal: J Clin Oncol Date: 2015-07-13 Impact factor: 44.544
Authors: Howard A Burris; Chandra P Belani; Peter A Kaufman; Alan N Gordon; Lee S Schwartzberg; Warren S Paroly; Seta Shahin; Lyndah Dreiling; Alan Saven Journal: J Oncol Pract Date: 2010-05 Impact factor: 3.840
Authors: Jenny M Whitworth; Kellie S Matthews; Kimberly A Shipman; T Michael Numnum; James E Kendrick; Larry C Kilgore; J Michael Straughn Journal: Gynecol Oncol Date: 2008-12-24 Impact factor: 5.482
Authors: Robert M Rifkin; Jeffrey Crawford; Reshma L Mahtani; David C Dale; Mohit Narang; William W MacLaughlin; Chanh Huynh; Prasad L Gawade; Sandra Lewis; Lucy DeCosta; Tatiana Lawrence; Rajesh Belani Journal: Support Care Cancer Date: 2022-06-22 Impact factor: 3.359